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Abstract
Objectives Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) have been associated with generalized and localized bone
loss. We conducted a comprehensive study using imaging (dual-energy X-ray absorptiometry, DXA) and laboratory biomarkers
in order to determine bone health and to study the effects of anti-tumor necrosis factor (TNF) biologics in RA and AS.
Patients and methods Thirty-six RA and 17 AS patients undergoing 1-year etanercept (ETN) or certolizumab-pegol (CZP)
therapy were studied. Bone density was assessed by DXA at baseline and after 12 months. Serum C-reactive protein (CRP),
calcium, phosphate, parathyroid hormone (PTH), vitamin D3, osteocalcin, procollagen type I N-propeptide (P1NP), C-terminal
telopeptide (βCTX), osteoprotegerin, sclerostin (SOST), Dickkopf-1 (DKK-1), soluble receptor activator nuclear kappa B ligand
(sRANKL), and cathepsin K (cathK) levels were determined at baseline and after 6 and 12 months.
Results TNF-α inhibition was clinically effective. Anti-TNF-α halted further bone loss over 1 year. In general, anti-TNF therapy
significantly increased P1NP, SOST levels, and the P1NP/βCTX ratios, while decreased DKK-1 and CathK production at
different time points in most patient subsets. In the full cohort and in RA, baseline and/or 12-month bone mineral density
(BMD) at multiple sites exerted inverse relationships with CRP and βCTX, and positive correlation with SOST. In AS, L2-4
BMD after 1-year biologic therapy inversely correlated with baseline βCTX, while femoral neck BMD rather showed inverse
correlations with CRP.
Conclusions Anti-TNF therapy slowed down generalized bone loss, in association with clinical improvements, in both diseases.
TNF blockade may enhance bone formation and suppress joint destruction. Anti-TNF therapy may act inversely on DKK-1 and
SOST. Independent predictors of BMD were SOST and βCTX in RA, whilst CRP in AS.
Key Points
• One-year anti-TNF therapy halted generalized bone loss in association with clinical improvement in arthritides.
• Anti-TNF therapy may inversely act on DKK-1 and SOST.
• Independent predictors of BMD were SOST and βCTX in RA, while CRP in AS.
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Introduction
Rheumatoid arthritis (RA) and ankylosing spondylitis (AS)
have been associated with osteoporosis, as well as localized
inflammatory bone resorption and/or formation [1, 2]. Low
bone mineral density (BMD) and increased fracture risk have
been observed in two-third of these patients [1, 2]. The
RANK-RANKL system is highly involved in inflammatory
bone resorption [3, 4]. Among cytokines, tumor necrosis
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factor α (TNF-α) induces bone loss via the stimulation of
RANKL [1, 3–5]. TNF-α also directly induces osteoclast
function [6, 7]. Interleukin-1 (IL-1), IL-6, and IL-17 also have
similar effects [4]. Osteoprotegerin (OPG), a decoy receptor of
RANKL, influences bone erosions in arthritides [8]. A low
OPG/RANKL ratio has been associated with increased radio-
graphic damage in RA [9, 10]. In clinical trials, TNF-α inhib-
itors inhibited bone destruction and reduced radiological pro-
gression in RA [11–13].
With respect to bone formation, wingless-related integra-
tion site (Wnt) proteins have emerged as central regulators.
Upon osteoblast activation, a multi-molecular complex is
formed. β-catenin becomes free, it stabilizes and it is
transported to the nucleus resulting in the transcription of
Wnt-induced genes regulating bone formation. This process
can be inhibited by Dickkopf-1 (DKK-1) and sclerostin
(SOST). DKK-1 and SOST are able to block the formation
of the molecular complex mentioned above and this complex
will fall into pieces [4, 14]. There is a direct interaction be-
tween DKK-1 and SOST. Blockade of DKK-1 in animal
models suppresses SOST production [15]. TNF-α induces
DKK-1 and DKK-1 stimulates SOST production by osteo-
cytes. Both DKK-1 and SOST block bone formation [14].
An interaction between DKK-1 and OPG was proposed in
experimental arthritis models suggesting that the
antiresorptive and bone formation-inducing property of
DKK-1 inhibition also involves OPG [16]. As TNF-α induces
DKK-1 and SOST and thus inhibits bone formation, in con-
trast to RA, there have been lots of controversies with regard
to the efficacy of TNF-α inhibitors in halting bone formation
and the development of syndesmophytes in axial AS [12, 14].
In animal models of arthritis, SOST promoted, while anti-
SOST attenuated the formation of erosions [17]. In contrast,
another study suggested that SOST may act differently by
inhibiting rather than promoting TNF-α-mediated inflamma-
tory bone loss [18]. SOST may exert diverse effects on bone
turnover under inflammatory and non-inflammatory
conditions.
In addition to their effects on localized bone turnover, anti-
TNF therapies also influence the development and progres-
sion of generalized osteoporosis in conjunction with RA and
AS [12].
Anti-TNF therapies may also influence bone turnover and
the production of bone biomarkers. Anti-TNF-α agents were
shown to increase serum osteocalcin (OC) and procollagen
type I N-propeptide (P1NP) levels, which are markers of bone
formation, and suppressed C-terminal telopeptide (βCTX)
and receptor activator nuclear kappa B ligand (RANKL)
levels, which are markers of bone resorption, in RA and AS
(reviewed in [12]). These findings were not always consistent
as some studies with TNF-α inhibitors showed no effects on
OC, P1NP and βCTX levels [19, 20]. On the other hand, anti-
TNF agents increased OPG/RANKL, OC/βCTX, and
P1NP/βCTX ratios [20–22]. Furthermore, TNF-α inhibitors
also suppress DKK-1 leading to increased bone formation in
RA [23, 24]. Interestingly, in one study, anti-TNF treatment
increased SOST production in RA [25]. In most studies,
changes in bone biomarkers by anti-TNF therapy were asso-
ciated with improvements in disease activity and inflammato-
ry markers (e.g. CRP) in RA and AS [12].
As most studies in the literature have been conducted in
either RA or AS/SpA, here, we conducted a comprehensive
study on the effects of anti-TNF biologics on bone density and
bone markers in both RA and AS. Moreover, we assessed
more than 10 bone markers in order to elucidate the complex
effects of biologics on bone metabolism. Our aim was to draw
a complex picture of, as well as to demonstrate the effects of
anti-TNF therapy on bone health in RA and AS.
Patients and methods
Patients
Fifty-three patients with inflammatory arthritis (36 RA and 17
AS) were enrolled in the study. Patient characteristics are seen
in Table 1. The cohort included 34 women and 19 men with
mean age of 52.0 ± 12.1 (range 24–83) years. Mean disease
duration was 8.5 ± 7.9 (range 1–44) years. Patients with active
disease were recruited prior to initiating a biological therapy.
Inclusion criteria included definitive diagnosis of RA or AS;
high disease activity (DAS28 > 5.1, BASDAI > 4 after at least
3 months of combined conventional DMARD therapy); clin-
ical indication of biological therapy. Exclusion criteria includ-
ed acute/recent infection, standard contraindications to anti-
TNF therapy, chronic renal or liver failure. None of the pa-
tients had known primary osteoporosis prior to the diagnosis
of RA or AS. None of the patients received replacement vita-
min D therapy at the time of inclusion. At baseline, RA pa-
tients had a mean DAS28 of 5.00 ± 0.86, while AS patients
exerted mean BASDAI of 5.79 ± 1.19. All patients were bio-
logic-naïve, started on an anti-TNF therapy at baseline and
received the same biological treatment at 1 year. Clinical as-
sessments were performed at baseline, and after 3, 6, and
12 months of therapy. Among the 36 RA patients, 20 received
etanercept (ETN) 50 mg/week subcutaneous (SC) and 16 re-
ceived certolizumab pegol (CZP) (400mg at 0, 2, and 4weeks,
and thererafter 200 mg twice weekly SC). Altogether 28 RA
patients were administered the TNF inhibitor in combination
with methotrexate (MTX). These patients had been on MTX
prior to the initiation of biologics and the MTX dose was not
changed. All 17 AS patients received ETN 50 mg/week SC in
monotherapy. Although most RA patients and some AS pa-
tients may have received corticosteroids prior to the study,
none of the patients were on corticosteroids for at least
3 months prior to and during the study. The study was
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approved by the Hungarian Scientific Research Council
Ethical Committee (approval no. 14804-2/2011/EKU).
Written informed consent was obtained from each patient
and assessments were carried out according to the declaration
of Helsinki.
Bone densitometry assessments
Dual energy X-ray absorptiometry examination was per-
formed using the LUNAR Prodigy (GE-Lunar Corp.,
Madison, WI, USA) densitometer by a single technician dur-
ing the study period. The coefficient of variation (CV) of the
technique at our institute was 0.8% using the anatomical spine
phantom measured daily and there was absence of machine
drift during the study. The short-term in vivo precision error
for L2-L4 lumbar spine is 0.012 g/cm2 (LSC = 0.034 g/cm2 at
95% confidence level) and femur neck is 0.013 g/cm2 (LSC =
0.035 g/cm2 at 95% confidence level).
Laboratory measurements and assessment of disease
activity
Blood was drawn after overnight fasting. Serum high sensi-
tivity C reactive protein (hsCRP; normal, ≤ 5 mg/l) and IgM
rheumatoid factor (RF; normal, ≤ 50 IU/ml) weremeasured by
quantitative nephelometry (Cobas Mira Plus-Roche), using
CRP and RF reagents (both Dialab). ACPA (anti-CCP) auto-
antibodies were detected in serum samples using a second-
generation Immunoscan-RA CCP2 ELISA test (Euro
Diagnostica; normal, ≤ 25 IU/ml). The assay was performed
according to the manufacturer’s instructions. Disease activity
of RA and AS was calculated as DAS28-ESR (3 variables)
and BASDAI, respectively [26].
Bone biomarkers
Blood was drawn after overnight fasting. Serum calcium
(Ca; Roche Diagnostics; normal, 2.1–2.6 mmol/l) and
phosphate (P; Roche Diagnost ics ; normal , 0 .8–
1.45 mmol/l); parathyroid hormone (PTH; Roche
Diagnostics; normal, 1.6–6.9 pmol/l); 25-hydroxy-
vitamin D3 (DiaSorin; normal, ≥ 75 nmol/l); osteocalcin
(OC; Roche Diagnostics; normal, < 41 μg/l), P1NP
(Roche Diagnostics; normal, < 75 μg/l), βCTX (Roche
Diagnostics; normal, < 0.57 μg/l), osteoprotegerin (OPG;
Biomedica; median, 2.7 pmol/l), sclerostin (SOST;
Biomedica; median, 24.14 pmol/l), DKK-1 (Biomedica;
median, 36 pmol/l), soluble RANKL (Ampli-sRANKL;
Biomedica; median, 0.14 pmol/l), and cathepsin K
(cathK; Biomedica; median, 8.7 pmol/l) were determined
by ELISA at baseline, 6 and 12 months after treatment
initiation. The above-mentioned reference values for bio-
chemical data were generated by the local laboratory.
Statistical analysis
Statistical analysis was performed using SPSS (IBM 22
software). Data are expressed as the mean ± SD for con-
tinuous variables and percentages for categorical vari-
ables. Continuous variables were evaluated by paired
two-tailed t test and the Wilcoxon test. Nominal vari-
ables were compared between groups using the
chi-squared or Fisher’s exact test, as appropriate.
Correlations were determined by Spearman’s analysis.
Univariate and multiple regression analysis using the
stepwise method was applied to investigate independent
associations between DXA measurements (dependent
variables) and laboratory parameters (independent vari-
ables). Sex and menopausal status were included in the
regression analyses. The β standardized linear coeffi-
cients showing linear correlations between two parame-
ters were determined. The B (+ 95% CI) regression co-
efficient indicated independent associations between de-
pendent and independent variables during changes. P
values < 0.05 were considered significant.
Table 1 Patient characteristics
RA AS Total
n 36 17 53
Female:male 31:5 3:14 34:19
Age (mean ± SEM) (range), years 55.9 ± 9.8 (35–83) 43.6 ± 12.4 (24–72) 52.0 ± 12.1 (24–83)
Postmenopausal female patients 26 1 27
Disease duration (mean ± SEM) (range), years 9.1 ± 8.3 (1–44) 7.2 ± 7.0 (1–26) 8.5 ± 7.9 (1–44)
RF positivity, n (%) 26 (72) – –
ACPA positivity, n (%) 21 (58) – –
DAS28 (baseline) (mean ± SEM) 5.00 ± 0.86 – –
BASDAI (baseline) (mean ± SEM) – 5.79 ± 1.19 –
Treatment (ETN, CZP) 20 ETN, 16 CZP 17 ETN 37 ETN, 16 CZP
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Results
Clinical response to anti-TNF therapy in RA and AS
TNF-α inhibition was highly effective in RA and AS patients.
In the RA cohort (n = 36), ETN and CZP treatment resulted in
significant decreases in DAS28 after 3 months (3.52 ± 0.79;
p < 0.001), 6 months (3.13 ± 0.84; p < 0.001) and 12 months
of treatment (3.02 ± 0.96; p < 0.001) compared with baseline
(5.00 ± 0.86) (data not shown). In RA, CRP at baseline (16.0
± 19.1 mg/l) was also significantly higher than after 3 months
(8.5 ± 11.3 mg/l; p < 0.001), 6 months (7.0 ± 7.1 mg/l; p =
0.005) and 12 months (7.5 ± 7.9 mg/l; p = 0.011) (data not
shown).
In AS (n = 17), BASDAI significantly decreased from 5.79
± 1.19 at baseline to 2.04 ± 0.89 (p < 0.001), 2.00 ± 1.03
(p < 0.001), and 1.86 ± 1.04 (p < 0.001) at 3, 6, and 12months,
respectively (data not shown). Moreover, CRP was also
higher at baseline (12.5 ± 12.0 mg/l) than after 3 months
(5.7 ± 13.6 mg/l; p = 0.026), 6 months (6.3 ± 13.5 mg/l; p =
0.041), and 12 months of therapy (4.4 ± 6.6 mg/l; p = 0.003)
(data not shown).
Fortunately, all RA and AS patients were responders and
no biologic switch was necessary in any of these patients
during the 1-year treatment period.
Effects of anti-TNF therapy on bone mineral density
While anti-TNF-α treatment halted further generalized bone
loss over 1 year in the whole cohort, there was no significant
difference in mean L2–4 vertebral and femoral neck BMD or
T-scores at baseline compared with 12months (L2–4 vertebral
BMD 0.890 ± 0.027 vs 0.889 ± 0.025 g/cm2 and T-score −
0.51 ± 0.21 vs − 0.46 ± 0.21; femoral neck BMD 0.842 ±
0.020 vs 0.838 ± 0.020 g/cm2 and T-score − 0.84 ± 0.17 vs −
0.89 ± 0.17, respectively). Similar observations were made in
the RA and AS subsets (data not shown).
Effects of biologics on bone biomarkers
Among the bone turnover (formation and resorption) markers,
in the full RA+AS cohort, one-year anti-TNF therapy signif-
icantly increased P1NP after 3 months (51.8 ± 22.5 μg/l; p =
0.042) and 6 months (53.5 ± 27.1 μg/l; p = 0.040) compared
with baseline (46.7 ± 19.3 μg/l) (Fig. 1). Similar differences in
P1NP levels could be observed in the RA subset after 3months
(52.2 ± 24.0 μg/l; p = 0.041) and 6 months (56.4 ± 29.0 μg/l;
p = 0.026) compared with baseline (45.6 ± 19.9 μg/l) (Fig. 1).
In AS, P1NP levels significantly increased after 12 months
(56.9 ± 28.8 μg/l; p = 0.035) versus baseline (49.2 ± 18.4 μg/
l) (Fig. 1). At the same time, OC and βCTX had normal levels
at all time points. Neither OC (baseline, 20.3 ± 8.8 μg/l;
12 months, 20.5 ± 9.8 μg/l) nor βCTX (baseline, 0.34 ±
0.18 μg/l; 12 months, 0.35 ± 0.18 μg/l) changed significantly
in the full RA+AS cohort.
With respect to the Wnt-β-catenin pathway and its regula-
tors, in the RA+AS cohort, DKK-1 levels were higher at base-
line (59.7 ± 28.6 pmol/l) compared with the reference value
described above. DKK-1 levels significantly decreased after
6 months of treatment (51.6 ± 25.5 pmol/l; p = 0.045) com-
pared with baseline (Fig. 2A). SOST levels were also higher
at baseline (94.6 ± 45.3 pmol/l) compared with the normal
Fig. 1 Effects of 1-year anti-TNF therapy on P1NP production. TNF
inhibition significantly increased P1NP levels in the RA+AS cohort
after 3 and 6 months of treatment; in RA patients after 3 and 6 months
and in AS, after 12 months
Fig. 2 Effects of anti-TNF therapy on DKK-1 and SOST levels. Anti-
TNF treatment significantly decreased DKK-1 production in the full
cohort and in the RA subset after 6 months (A). TNF inhibition also
increased SOST levels in the RA+AS, RA, and AS subsets after
12 months (B)
Clin Rheumatol
reference value. Conversely to DKK-1, SOST levels signifi-
cantly increased after 12 months (112.4 ± 76.1 pmol/l; p =
0.035) versus baseline (Fig. 2B). In RA, DKK-1 also signifi-
cantly decreased after 6 months (52.1 ± 26.1 pmol/l; p =
0.042) versus baseline (60.6 ± 28.9 pmol/l) (Fig. 2A). On the
other hand, SOST significantly increased after 12 months
(128.5 ± 83.7 pmol/l; p = 0.038) versus baseline (107.0 ±
47.5 pmol/l) (Fig. 2B). In AS, SOST significantly increased
after 12 months (81.3 ± 46.9 pmol/l; p = 0.034) compared
with baseline (70.6 ± 29.0 pmol/l) (Fig. 2B).
In the full cohort, the baseline concentrations of CathK
(27.4 ± 6.8 pmol/l) were higher compared with the normal
reference value above. There was a significant decrease in
CathK production after 12 months (25.8 ± 5.5 pmol/l; p =
0.006) compared with baseline (Fig. 3). In RA, CathK also
significantly decreased after 12 months (26.9 ± 5.6 pmol/l;
p = 0.012) versus baseline (28.7 ± 6.2 pmol/l) (Fig. 3).
With respect to the RANKL pathway, in the full cohort or
in RA or AS patients, sRANKL and OPG levels did not show
any differences during anti-TNF therapy. In addition, Ca, P,
vitamin D3 and PTH levels also did not change during the 1-
year period (data not shown).
When calculating bone formation/resorption ratios
(P1NP/βCTX, OC/βCTX and OPG/RANKL), which better
reflect bone turnover changes, in the full cohort, the
P1NP/βCTX ratio significantly increased at 6 months
(187.5 ± 85.5; p = 0.032) compared with baseline (160.8 ±
56.5) (Fig. 4). In RA, the P1NP/βCTX ratio significantly in-
creased after 6 months (190.2 ± 87.2; p = 0.035) (Fig. 4). In
addition, the OC/βCTX and OPG/RANKL ratios did not
change significantly during the 12 months in the full cohort,
RA or AS (data not shown).
Correlations between bone mineral density
and laboratory biomarkers
Univariate and multiple regression analyses were performed
in order to determine associations between BMD at various
sites (dependent variables) and laboratory parameters (inde-
pendent variables) (Table 2). In the full cohort and in RA
patients, baseline and/or 12-month BMD at multiple sites
exerted inverse relationships with CRP and βCTX, as well
as positive correlations with SOST. In the AS subset, L2–4
BMD after 1-year biologic therapy inversely correlated with
baseline βCTX. Femoral neck BMD rather showed inverse
correlations with CRP. The actual data and p values are in-
cluded in Table 2.
Discussion
RA and AS have been associated with secondary osteoporosis
and increased fracture risk [1, 2]. Inflammatory bone forma-
tion is also a hallmark of AS [12, 14]. Anti-TNF biologics
may inhibit bone loss, but they exert limited effects on inflam-
matory bone formation [12]. Furthermore, biological therapy
may affect the production of bonemarkers in RA and AS [12].
With respect to mode of action, TNF inhibitors decrease
RANKL and increase OPG expression in inflammatory dis-
eases [12]. TNF inhibition also results in blockade of DKK-1
and stimulation of Wnt-dependent bone formation [12].
In this study, we assessed the effects of ETN or CZP ther-
apy on disease activity, bone loss and bone biomarkers in RA
and AS. As expected, 1-year anti-TNF treatment was effective
in both RA and AS patients as it significantly decreased
DAS28 and BASDAI, respectively. These effects of ETN
and CZP were observed as early as after 3 months. The anti-
inflammatory effects of anti-TNF therapy were accompanied
by inhibition of bone loss in both diseases. L2–4 and femoral
neck BMD remained unchanged after 1-year ETN or CZP
therapy in the entire cohort, as well as in RA and AS. These
effects have previously been reported by others [12, 13].
Baseline CRP inversely correlated not only with baseline
L2–4 and femoral neck BMD, but also with BMD after 1-
year treatment. Thus, at baseline, high-grade inflammation
correlated with low BMD. Moreover, we found that baseline
Fig. 3 Effects of 1-year anti-TNF therapy on cathepsin K (CathK)
production. TNF inhibition significantly decreased CathK levels in the
RA+AS cohort and in RA patients after 12 months of treatment
Fig. 4 Effects of 1-year anti-TNF therapy on P1NP/βCTX ratios. TNF
inhibition significantly increased P1NP/βCTX in the RA+AS cohort and
in RA patients after 6 months of treatment
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CRP may predict further bone loss after 1-year anti-TNF
therapy.
The first publications on the effects of TNF inhibitors on
bone and osteoporosis were published in the 2000s. In most
studies, effects on the bone have been associated with favor-
able clinical responses. A great amount of data have been
published on infliximab, ETN, adalimumab and some data
also on golimumab (reviewed in [12]). We have not found
any reports on the bone effects of CZP.
Regarding bone biomarkers, 1-year anti-TNF therapy sig-
nificantly increased P1NP over time in our full cohort, in RA
andAS. Other markers of bone turnover, such as OC orβCTX
did not change upon anti-TNF therapy. The P1NP/βCTX ratio
increased over time in the full cohort and in RA. Bone resorb-
ing activity as indicated by βCTX at baseline was associated
with low baseline BMD and we showed that baseline βCTX
may also predict further bone loss after 1-year anti-TNF ther-
apy. In line with our findings, previous studies found that TNF
inhibitors increased serum P1NP levels and, in some cohorts,
suppressed βCTX levels in RA and AS [20, 21, 23, 27–32].
These findings were not always consistent as some other stud-
ies showed no effects of TNF-α inhibitors on OC, P1NP, and
βCTX levels [19, 20]. Furthermore, anti-TNF agents have
been shown to increase OPG/RANKL, OC/βCTX, and
P1NP/βCTX ratios [20–22]. In most studies, changes in bone
biomarkers by anti-TNF therapy were associated with im-
provements in disease activity in RA and AS [12].
With respect to DKK-1 and SOST, upon 1-year ETN or
CZP treatment, DKK-1 levels transiently decreased in the
whole cohort and in the RA subset. On the other hand,
SOST levels significantly increased in the entire cohort, as
well as in the RA and AS subsets after 12 months of treat-
ment. When comparing RA and AS, SOST levels were low-
er at all time points in AS compared with RA. Baseline
SOSTcorrelated with L2–4 and femoral neck BMD at base-
line, as well as after 12 months in the whole cohort and in
RA. This association was further confirmed by regression
analyses. Interestingly, higher baseline SOST was
Table 2 Regression analysis of CRP, bone density and biomarker values
Dependent variable Independent variable Univariate Multiple
B (95% CI) β p B (95% CI) β p
A. All patients (n = 53)
L2–4 BMD (baseline) CRP (baseline) − 0.004 (− 0.006 to − 0.001) − 0.332 0.020
βCTX (baseline) − 0.498 (− 0.809 to − 0.187) − 0.426 0.002 − 0.498 (− 0.809 to − 0.187) − 0.426 0.002
SOST (baseline) 0.001 (0–0.003) 0.342 0.025
L2–4 BMD (12 months) CRP (baseline) − 0.003 (− 0.006–0) − 0.285 0.047
βCTX (baseline) − 0.449 (− 0.750 to − 0.147) − 0.400 0.004
Femoral neck BMD (baseline) CRP (baseline) − 0.002 (− 0.005–0) − 0.303 0.033
SOST (baseline) 0.001 (0–0.002) 0.308 0.042 0.001 (0–0.002) 0.308 0.042
Femoral neck BMD (12 months) CRP (baseline) − 0.003 (− 0.005 to − 0.001) − 0.396 0.004 − 0.002 (− 0.005–0) − 0.299 0.036
βCTX (baseline) − 0.282 (− 0.528 to − 0.037) − 0.317 0.025 − 0.278 (− 0.536 to − 0.020) − 0.303 0.035
SOST (baseline) 0.001 (0–0.002) 0.343 0.024
B. RA (n = 36)
L2–4 BMD (baseline) CRP (baseline) − 0.003 (− 0.006–0) − 0.331 0.049
βCTX (baseline) − 0.524 (− 0.853 to − 0.194) − 0.485 0.003 − 0.342 (− 0.666 to − 0.017) − 0.375 0.040
SOST (baseline) 0.002 (0.001–0.003) 0.517 0.003 0.001 (0–0.002) 0.374 0.041
L2–4 BMD (12 months) βCTX (baseline) − 0.478 (− 0.081 to − 0.145) − 0.448 0.006 − 0.335 (− 0.669 to − 0.001) − 0.362 0.049
SOST (baseline) 0.001 (0–0.002) 0.360 0.047 0.001 (0–0.002) 0.384 0.038
Femoral neck BMD (baseline) SOST (baseline) 0.001 (0–0.002) 0.375 0.038 0.001 (0–0.002) 0.402 0.021
Femoral neck BMD (12 months) CRP (baseline) − 0.003 (− 0.005–0) − 0.353 0.035
βCTX (baseline) − 0.324 (− 0.617 to − 0.031) − 0.359 0.031 − 0.434 (− 0.738 to − 0.130) − 0.457 0.007
SOST (baseline) 0.001 (0–0.002) 0.422 0.018
C. AS (n = 17)
L2–4 BMD (12 months) βCTX (baseline) − 0.858 (− 1.600 to − 0.117) − 0.609 0.027
Femoral neck BMD (baseline) CRP (baseline) − 0.006 (− 0.011 to − 0.001) − 0.589 0.027 − 0.006 (− 0.011 to − 0.001) − 0.589 0.027
Femoral neck BMD (12 months) CRP (baseline) − 0.006 (− 0.011 to − 0.001) − 0.597 0.024 0.001 (− 0.007–0) − 0.359 0.034
β, standardized linear coefficient; B (+ 95% CI), regression coefficient
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associated with higher BMD at all sites. Moreover, high
baseline SOST predicted higher BMD after 12 months of
anti-TNF treatment. Similar to our observations, other stud-
ies in RA also reported that TNF-α inhibitors suppressed
DKK-1 leading to increased bone formation [23, 24]. In
addition, in one study, anti-TNF treatment increased SOST
production in RA [25]. The seemingly controversial effects
of anti-TNF biologics on DKK-1 and SOST need further
discussion. In general, DKK-1 and SOST were thought to
have unidirectional effects on the bone. Both molecules
were described to block Wnt-β-catenin-dependent bone
formation. TNF-α may induce both DKK-1 and SOST pro-
duction [14]. DKK-1 may directly drive SOST expression
by osteocytes and DKK-1 blockade also inhibits SOST pro-
duction [14, 15]. Indeed, Chen et al. [17] administered anti-
SOSTantibody to human TNF transgenic mice that develop
inflammatory arthritis. In this model, anti-SOST did not
affect synovitis. However, anti-SOST, but not anti-TNF an-
tibodies halted the progression of bone erosions [17]. On the
other hand, more recently, Wehmeyer et al. [18] reported
that in a TNF-α-dependent murine arthritis model, where
synovial fibroblasts abundantly produce SOST, SOST inhi-
bition leads to accelerated synovitis and joint destruction.
SOST blocked TNF-α-dependent signaling pathways and
SOST inhibition ameliorated arthritis in an animal model
[18]. Moreover, low SOST and DKK-1 production have
been associated with syndesmophyte formation in AS
[33]. SOST levels remain low after TNF-α blockade, which
may partly explain the inefficacy of TNF inhibitors on bone
formation in AS [34, 35]. Interestingly, low SOST and
DKK-1 levels in AS result in increased CRP production
[35]. Indeed, SOST levels increased in our study in both
AS and RA; however, the absolute serum concentrations
of SOST were lower in AS vs RA at all time points. Our
findings that TNF-α inhibitors may differentially regulate
DKK-1 and SOST suggest that, apart from the direct stimu-
latory effect of DKK-1 on SOST [14, 15], there may be
other indirect regulatory mechanisms between these two
molecules. Finally, in our cohort, high SOSTcorrelated with
high BMD at all sites. This finding supports previous obser-
vations that, while under non-inflammatory conditions,
such as osteoporosis, SOST inhibits Wnt-mediated bone
formation and contributes to bone loss and joint destruction
[18, 36, 37], under TNF-dependent inflammatory condi-
tions, SOST may preserve bone [18] and attenuate joint
damage [18]. Furthermore, anti-TNF treatment may in-
crease SOST levels [25] and, as we demonstrated in this
study, high SOST may correlate with high BMD.
When comparing bone resorption indicated by βCTX with
bone formation associated with SOST, only βCTX, but not OC,
and only SOST, but not DKK-1 correlated with BMD. Thus, our
data suggest that βCTX and SOST, in addition to CRP, may be
the most important biomarkers and independent predictors of
BMD. Moreover, most of these associations were seen in the
entire cohort, where two-third of the patients had RA, and in
the RA subset alone. Interestingly only βCTX and SOST, but
not CRP associated with BMD in RA. In contrast, in our rela-
tively small AS subset, only CRP, but not βCTX or SOST cor-
related with femoral neck BMD. In conclusion, in RA, SOST
and βCTX, but not CRP are independent predictors of BMD (at
baseline and after 12 months), whilst, in AS, CRP may serve as
the best biomarker of inflammatory bone metabolism. As men-
tioned above, low SOSTand DKK-1 levels in ASmay stimulate
CRP production [35], this may further explain the outstanding
importance of CRP in AS-related bone changes.
CathK is a matrix-degrading enzyme that effectively di-
gests collagen. CathK has been implicated in osteoporosis
and a CathK inhibitor, odanacatib, has been tried in postmen-
opausal osteoporosis [38]. In RA, increased CathK levels cor-
related with joint damage [39]. CathK is strongly expressed at
different spinal regions in AS [40]. In our entire cohort and in
the RA subset, but not in AS, TNF inhibition resulted in sig-
nificantly decreased CathK levels after 1 year. In a study of 13
AS patients, infliximab, ETN, or adalimumab treatment did
not change CathK levels [41]. We did not find any reports in
the literature on the effects of biologics on CathK production.
Our study has advantages and limitations. We included RA
and AS patients and compared the two disease. To our knowl-
edge, this is the first study that assesses the effects of CZP on
bone loss. Moreover, we determined a high number of bone
biomarkers in these patients and correlated inflammatory and
bone biomarkers with BMD. Finally, we developed a potential
explanation on the differing effects of SOST in inflammatory
vs non-inflammatory bone loss. This study certainly has lim-
itations, primarily the relatively low number of patients.
However, we assessed BMD, as well as a great number of
biomarkers in a prospective manner, which would have been
more difficult in a larger patient cohort.
In summary, despite its diverse effects on bone formation in
RA and AS, anti-TNF therapy (ETN and CZP) slowed down
bone loss in both diseases. Independent predictors of BMD
were SOST and βCTX in RA, whilst CRP in AS. Further
studies are needed to evaluate the potential beneficial effects
of biologics on inflammatory bone loss.
Funding information Open access funding provided by University of
Debrecen (DE). This research was supported by the Hungarian National
Scientific Research Fund (OTKA) grant No. K 105073 (H.P.B. and Z.S.);
by the European Union and the State of Hungary and co-financed by the
European Social Fund in the framework of TAMOP-4.2.4.A/2-11/1-
2012-0001 ‘National Excellence Program’(Z.S.); and by the European
Union grants GINOP-2.3.2-15-2016-00015 and GINOP-2.3.2-15-2016-
00050 (Z.S.).
Compliance with ethical standards
Disclosures None.
Clin Rheumatol
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Deal C (2012) Bone loss in rheumatoid arthritis: systemic,
periarticular, and focal. Curr Rheumatol Rep 14(3):231–237
2. Magrey M, Khan MA (2010) Osteoporosis in ankylosing spondy-
litis. Curr Rheumatol Rep 12(5):332–336
3. Schett G, Hayer S, Zwerina J, Redlich K, Smolen JS (2005)
Mechanisms of disease: the link between RANKL and arthritic
bone disease. Nat Clin Pract Rheumatol 1(1):47–54
4. Takayanagi H (2009) Osteoimmunology and the effects of the im-
mune system on bone. Nat Rev Rheumatol 5(12):667–676
5. Daoussis D, Andonopoulos AP, Liossis SN (2010) Wnt pathway
and IL-17: novel regulators of joint remodeling in rheumatic dis-
eases. Looking beyond the RANK-RANKL-OPG axis. Semin
Arthritis Rheum 39(15):369–383
6. Kobayashi K, Takahashi N, Jimi E, UdagawaN, TakamiM, Kotake
S, Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H,
Morinaga T, Higashio K, Martin TJ, Suda T (2000) Tumor necrosis
factor alpha stimulates osteoclast differentiation by a mechanism
independent of the ODF/RANKL-RANK interaction. J Exp Med
191(2):275–286
7. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum
SL (2000) TNF-alpha induces osteoclastogenesis by direct stimu-
lation of macrophages exposed to permissive levels of RANK li-
gand. J Clin Invest 106(12):1481–1488
8. Schett G, Redlich K, Smolen JS (2003) The role of osteoprotegerin
in arthritis. Arthritis Res Ther 5(5):239–245
9. van Tuyl LH, Voskuyl AE, Boers M, Geusens P, Landewe RB,
Dijkmans BA et al (2010) Baseline RANKL:OPG ratio and
markers of bone and cartilage degradation predict annual radiolog-
ical progression over 11 years in rheumatoid arthritis. Ann Rheum
Dis 69(9):1623–1628
10. Geusens PP, Landewe RB, Garnero P, Chen D, Dunstan CR, Lems
WF et al (2006) The ratio of circulating osteoprotegerin to RANKL
in early rheumatoid arthritis predicts later joint destruction. Arthritis
Rheum 54(6):1772–1777
11. Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou
K, Dougados M et al (2017) EULAR recommendations for the
management of rheumatoid arthritis with synthetic and biological
disease-modifying antirheumatic drugs: 2016 update. Ann Rheum
Dis 76(6):960–977
12. Szentpetery A, Horvath A, Gulyas K, Petho Z, Bhattoa HP, Szanto
S et al (2017) Effects of targeted therapies on the bone in arthritides.
Autoimmun Rev 16(3):313–320
13. Haugeberg G, Helgetveit KB, Forre O, Garen T, Sommerseth H,
Proven A (2014) Generalized bone loss in early rheumatoid arthritis
patients followed for ten years in the biologic treatment era. BMC
Musculoskelet Disord 15:289
14. Schett G, Gravallese E (2012) Bone erosion in rheumatoid arthritis:
mechanisms, diagnosis and treatment. Nat Rev Rheumatol 8(11):
656–664
15. HeilandGR, ZwerinaK, BaumW,Kireva T, Distler JH, Grisanti M,
Asuncion F, Li X, Ominsky M, Richards W, Schett G, Zwerina J
(2010) Neutralisation of Dkk-1 protects from systemic bone loss
during inflammation and reduces sclerostin expression. Ann
Rheum Dis 69(12):2152–2159
16. Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D,
Korb A, Smolen J, Hoffmann M, Scheinecker C, van der Heide D,
Landewe R, Lacey D, RichardsWG, Schett G (2007) Dickkopf-1 is
a master regulator of joint remodeling. Nat Med 13(2):156–163
17. Chen XX, Baum W, Dwyer D, Stock M, Schwabe K, Ke HZ,
Stolina M, Schett G, Bozec A (2013) Sclerostin inhibition reverses
systemic, periarticular and local bone loss in arthritis. Ann Rheum
Dis 72(10):1732–1736
18. Wehmeyer C, Frank S, Beckmann D, Bottcher M, Cromme C,
Konig U et al (2016) Sclerostin inhibition promotes TNF-
dependent inflammatory joint destruction. Sci Transl Med 8(330):
330ra35
19. Marotte H, Pallot-Prades B, Grange L, Gaudin P, Alexandre C,
Miossec P (2007) A 1-year case-control study in patients with rheu-
matoid arthritis indicates prevention of loss of bone mineral density
in both responders and nonresponders to infliximab. Arthritis Res
Ther 9(3):R61
20. Chopin F, Garnero P, le Henanff A, Debiais F, Daragon A, Roux C,
Sany J, Wendling D, Zarnitsky C, Ravaud P, Thomas T (2008)
Long-term effects of infliximab on bone and cartilage turnover
markers in patients with rheumatoid arthritis. Ann Rheum Dis
67(3):353–357
21. VisM, Havaardsholm EA, Haugeberg G, Uhlig T, Voskuyl AE, van
de Stadt RJ, Dijkmans BAC, Woolf AD, Kvien TK, Lems WF
(2006) Evaluation of bone mineral density, bone metabolism, oste-
oprotegerin and receptor activator of the NF kappa B ligand serum
levels during treatment with infliximab in patients with rheumatoid
arthritis. Ann Rheum Dis 65(11):1495–1499
22. Woo JH, Lee HJ, Sung IH, Kim TH (2007) Changes of clinical
response and bone biochemical markers in patients with ankylosing
spondylitis taking etanercept. J Rheumatol 34(8):1753–1759
23. Wang SY, Liu YY, Ye H, Guo JP, Li R, Liu X et al (2011)
Circulating Dickkopf-1 is correlated with bone erosion and inflam-
mation in rheumatoid arthritis. J Rheumatol 38(5):821–827
24. Garnero P, Tabassi NC, Voorzanger-Rousselot N (2008) Circulating
dickkopf-1 and radiological progression in patients with early rheuma-
toid arthritis treated with etanercept. J Rheumatol 35(12):2313–2315
25. Lim MJ, Kwon SR, Joo K, Son MJ, Park SG, Park W (2014) Early
effects of tumor necrosis factor inhibition on bone homeostasis after
soluble tumor necrosis factor receptor use. Korean J Intern Med
29(6):807–813
26. Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de
Putte LB, van Riel PL (1995) Modified disease activity scores that
include twenty-eight-joint counts. Development and validation in a
prospective longitudinal study of patients with rheumatoid arthritis.
Arthritis Rheum 38(1):44–48
27. Torikai E, Kageyama Y, Takahashi M, Suzuki M, Ichikawa T,
Nagafusa T, Nagano A (2006) The effect of infliximab on bone
metabolism markers in patients with rheumatoid arthritis.
Rheumatology (Oxford) 45(6):761–764
28. Visvanathan S, van der Heijde D, Deodhar A, Wagner C, Baker
DG, Han J, Braun J (2009) Effects of infliximab on markers of
inflammation and bone turnover and associations with bonemineral
density in patients with ankylosing spondylitis. Ann Rheum Dis
68(2):175–182
29. Visvanathan S, Wagner C, Marini JC, Baker D, Gathany T, Han J
et al (2008) Inflammatory biomarkers, disease activity and spinal
disease measures in patients with ankylosing spondylitis after treat-
ment with infliximab. Ann Rheum Dis 67(4):511–517
30. Barnabe C, Hanley DA (2009) Effect of tumor necrosis factor alpha
inhibition on bone density and turnover markers in patients with
rheumatoid arthritis and spondyloarthropathy. Semin Arthritis
Rheum 39(2):116–122
Clin Rheumatol
31. Vis M, Wolbink GJ, Lodder MC, Kostense PJ, van de Stadt RJ, de
Koning MH et al (2003) Early changes in bone metabolism in
rheumatoid arthritis patients treated with infliximab. Arthritis
Rheum 48(10):2996–2997
32. Seriolo B, Paolino S, Sulli A, Ferretti V, Cutolo M (2006) Bone
metabolism changes during anti-TNF-alpha therapy in patients with
active rheumatoid arthritis. Ann N YAcad Sci 1069:420–427
33. Heiland GR, Appel H, Poddubnyy D, Zwerina J, Hueber A, Haibel
H, Baraliakos X, Listing J, Rudwaleit M, Schett G, Sieper J (2012)
High level of functional dickkopf-1 predicts protection from
syndesmophyte formation in patients with ankylosing spondylitis.
Ann Rheum Dis 71(4):572–574
34. Saad CG, Ribeiro AC, Moraes JC, Takayama L, Goncalves CR,
RodriguesMB et al (2012) Low sclerostin levels: a predictivemark-
er of persistent inflammation in ankylosing spondylitis during anti-
tumor necrosis factor therapy? Arthritis Res Ther 14(5):R216
35. Klingberg E, Nurkkala M, Carlsten H, Forsblad-d'Elia H (2014)
Biomarkers of bone metabolism in ankylosing spondylitis in rela-
tion to osteoproliferation and osteoporosis. J Rheumatol 41(7):
1349–1356
36. Piters E, Boudin E, Van Hul W (2008) Wnt signaling: a win for
bone. Arch Biochem Biophys 473(2):112–116
37. Lerner UH, Ohlsson C (2015) The WNT system: background and
its role in bone. J Intern Med 277(6):630–649
38. Perez-Castrillon JL, Pinacho F, De Luis D, Lopez-Menendez M,
Duenas LA (2010) Odanacatib, a new drug for the treatment of
osteoporosis: review of the results in postmenopausal women. J
Osteoporos 2010:1–5
39. Skoumal M, Haberhauer G, Kolarz G, Hawa G, Woloszczuk W,
Klingler A (2005) Serum cathepsin K levels of patients with
longstanding rheumatoid arthritis: correlation with radiological de-
struction. Arthritis Res Ther 7(1):R65–R70
40. Neidhart M, Baraliakos X, Seemayer C, Zelder C, Gay RE, Michel
BA, Boehm H, Gay S, Braun J (2009) Expression of cathepsin K
and matrix metalloproteinase 1 indicate persistent osteodestructive
activity in long-standing ankylosing spondylitis. Ann Rheum Dis
68(8):1334–1339
41. Wendling D, Cedoz JP, Racadot E (2008) Serum levels of MMP-3
and cathepsin K in patients with ankylosing spondylitis: effect of
TNF alpha antagonist therapy. Joint Bone Spine 75(5):559–562
Publisher’s note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
Affiliations
Katalin Gulyás1,2 & Ágnes Horváth1 & Edit Végh1 & Anita Pusztai1 & Ágnes Szentpétery1,3,4 & Zsófia Pethö1 &
Andrea Váncsa1 & Nóra Bodnár1 & Péter Csomor1 & Attila Hamar1 & Levente Bodoki1 & Harjit Pal Bhattoa5 &
Balázs Juhász6 & Zoltán Nagy1 & Katalin Hodosi1 & Tamás Karosi7 & Oliver FitzGerald4 & Gabriella Szücs1 &
Zoltán Szekanecz1 & Szilvia Szamosi1 & Sándor Szántó1,2
1 Division of Rheumatology, Department of Internal Medicine,
Faculty of Medicine, University of Debrecen, Nagyerdei str 98,
Debrecen 4032, Hungary
2 Department of Sports Medicine, Debrecen, Hungary
3 Department of Rheumatology, Uppsala University Hospital,
Uppsala, Sweden
4 Department of Rheumatology, St. Vincent’s University Hospital and
Conway Institute for Biomolecular Research, University College
Dublin, Dublin, Ireland
5 Department of Laboratory Medicine, Faculty of Medicine,
University of Debrecen, Debrecen, Hungary
6 Department of Oncology, Faculty of Medicine, University of
Debrecen, Debrecen, Hungary
7 Department of Otolaryngology, Borsod County Teaching Hospital,
Miskolc, Hungary
Clin Rheumatol
